Centro de Atención e Investigación Médica CAIMED, Chía, Colombia.
Amgen Biotecnológica SAS, Carrera 7 #123-35, piso 6, Bogotá, Colombia.
BMC Health Serv Res. 2023 May 23;23(1):529. doi: 10.1186/s12913-023-09454-z.
Febrile neutropenia associated with some chemotherapy regimens can lead to potentially fatal complications and high health care costs. Administration of pegfilgrastim using an On-Body Injector (OBI) may be more convenient for cancer patients and physicians in countries with limited access to high-complexity healthcare. This study aims to describe physician and nurse preferences regarding different options for administration of pegfilgrastim at cancer centers, the chemotherapy schemes for which pegfilgrastim is most frequently prescribed and how healthcare providers prioritize certain administration schemes according to patients' access to healthcare services.
Observational, descriptive, cross-sectional study and survey, conducted between 2019 and 2020, to describe physician and nurse preferences regarding options for administration of pegfilgrastim at cancer centers, the demographics of the study population and characteristics of participating cancer centers. It included 60 healthcare professionals practicing at oncology centers from 8 cities in Colombia who were contacted and surveyed via telephone. Quantitative continuous variables were summarized using central tendency and dispersion measures.
It was found that 35% of participants are haemato-oncologists, oncologists or hematologists, 30% are general practitioners, and 35% are other healthcare professionals (i.e., nurse, oncology nurse and head nurse). Our study shows that 48% of physicians prefer the use of OBI, particularly in the scheme of 24 h after myelosuppressive chemotherapy administrations. Regardless of patient frailty and travel time to the clinic, over 90% of healthcare providers (HCPs) prefer to prioritize preventing the patient from having to return to the clinic for pegfilgrastim administration as well as to increase healthcare staff availability through the use of OBI.
The present study is the first one in Colombia that sought the reasons behind HCPs' choice to use OBI pegfilgrastim. Our results indicate that most professionals prefer to avoid the patient having to re-enter the care center for pegfilgrastim administration to facilitate access to healthcare for patients; patient characteristics and ease of transport are determining factors for respondents when choosing an option for drug administration. We found OBI is the preferred alternative by most HCPs and a good resource optimization strategy in the context of cancer patients' health care in Colombia.
某些化疗方案引起的发热性中性粒细胞减少症可能导致潜在的致命并发症和高昂的医疗保健费用。在医疗保健服务复杂程度有限的国家，使用 Pegfilgrastim 体注射装置（OBI）给药可能对癌症患者和医生更为方便。本研究旨在描述癌症中心中医生和护士对 Pegfilgrastim 给药选择的偏好，最常开具 Pegfilgrastim 的化疗方案，以及根据患者获得医疗服务的机会，医疗保健提供者如何优先考虑某些给药方案。
这是一项于 2019 年至 2020 年期间进行的观察性、描述性、横断面研究和调查，旨在描述癌症中心中医生和护士对 Pegfilgrastim 给药选择的偏好、研究人群的人口统计学特征以及参与癌症中心的特征。该研究纳入了来自哥伦比亚 8 个城市的 60 名在肿瘤中心执业的医疗保健专业人员，通过电话联系并进行了调查。定量连续变量采用集中趋势和离散度指标进行总结。
结果发现，35%的参与者为血液科肿瘤医生、肿瘤医生或血液学家，30%为全科医生，35%为其他医疗保健专业人员（即护士、肿瘤护士和护士长）。我们的研究表明，48%的医生更喜欢使用 OBI，特别是在骨髓抑制化疗后 24 小时内的方案中。无论患者的虚弱程度和前往诊所的旅行时间如何，超过 90%的医疗保健提供者（HCPs）更愿意优先考虑避免患者因 Pegfilgrastim 给药而不得不返回诊所，并通过使用 OBI 增加医疗保健人员的可用性。
本研究是哥伦比亚首次研究 HCPs 选择使用 OBI Pegfilgrastim 的原因。我们的结果表明，大多数专业人员更愿意避免患者因 Pegfilgrastim 给药而不得不重新进入护理中心，从而为患者提供便利的医疗服务；患者的特征和运输的便利性是受访者选择药物给药选择的决定因素。我们发现，OBI 是大多数 HCPs 的首选替代方案，也是哥伦比亚癌症患者医疗保健中优化资源的良好策略。
Zotero 插件
